Publikasi Scopus FKUI 2021 per tanggal 31 Agustus 2021 (582 artikel)

Hidayat M., Handayani D., Nurwidya F., Andarini S.L.
56435992700;57219413838;55221773800;8716259500;
Hyperinflammation syndrome in covid-19 disease: Pathogenesis and potential immunomodulatory agents [Covid-19 hastalığında hiperenflamasyon sendromu: Patogenez ve potansiyel immünomodülatuvar ajanlar]
2021
Turkish Journal of Immunology
9
1
1
11
Faculty of Medicine, University of Mataram, Indonesia; Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia-Persahabatan Hospital, Jakarta, Indonesia
Hidayat, M., Faculty of Medicine, University of Mataram, Indonesia; Handayani, D., Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia-Persahabatan Hospital, Jakarta, Indonesia; Nurwidya, F., Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia-Persahabatan Hospital, Jakarta, Indonesia; Andarini, S.L., Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia-Persahabatan Hospital, Jakarta, Indonesia
The coronavirus disease 2019 (COVID-19) pandemic caused by infection of the SARS-CoV-2 virus has affected millions of people in the world. The pathogenesis and clinical manifestations of COVID-19 disease are tightly influenced by the host immune response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. In some condition, the immune response might be uncontrolled, giving rise to hyperinflammatory conditions marked by excessive release of proinflammatory cytokines (cytokine storms) in severe COVID-19 patients, which then can cause acute respiratory distress syndrome (ARDS), multiorgan failure, and death. Furthermore, treatment using immunomodulator agents including immunostimulatory and immunosuppressive agents can be an option in achieving successful treatment. In this review, we discuss the pathogenesis of the disease, including host immune responses to SARS-CoV-2 virus infection, and immune mechanisms which contribute to the disease severity and death as well as several potential immunomodulatory agents which can be used in the management of hyperinflammatory syndrome of severe COVID-19. © Turkish Journal of Immunlogy.
Coronavirus disease 2019 (COVID-19); Cytokine storm; Hyperinflammation syndrome; Immunomodulatory treatment
chloroquine; convalescent plasma; hydroxychloroquine; immunoglobulin; immunomodulating agent; interferon; interleukin 1 receptor blocking agent; interleukin 6 antibody; neutralizing antibody; sarilumab; tocilizumab; tumor necrosis factor inhibitor; adult respiratory distress syndrome; antibody dependent enhancement; coronavirus disease 2019; cytokine production; cytokine release; cytokine storm; disease severity; human; hyperinflammatory syndrome; immune response; immune system; immunosuppressive treatment; mortality; multiple organ failure; pandemic; Review; Severe acute respiratory syndrome coronavirus 2; signal transduction; stem cell transplantation; virus cell interaction; virus pathogenesis; virus replication
Turkish Society of Immunology
1301109X
Review
Q4
115
27813